DOCSLIB.ORG

Effect of Pritelivir Compared with Valacyclovir On

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effect of Pritelivir Compared with Valacyclovir On Version 1.0 + Amnd 1.0 Clinical Trial Protocol + Amnd 2.0, 3.0 + 4.0 AIC316-01-II-02 May 02, 2013 CLINICAL TRIAL PROTOCOL A double-blind, double dummy, randomized cross-over trial to compare the effect of AIC316 100 mg once daily versus valacyclovir 500 mg once daily on genital HSV shedding in HSV-2 seropositive adults. Trial No./Trial Identification Code: AIC316-01-II-02 Sponsor AiCuris GmbH & Co. KG Friedrich-Ebert-Str. 475 / Building 302 42117 Wuppertal Germany Sponsor Contact Burkhard Timmler, MD Medical Director AiCuris GmbH & Co. KG Friedrich-Ebert-Str. 475 / Building 302 42117 Wuppertal Germany Phone: +49 202 31763 FAX: +49 202 31763 Contract Research Organization Clinical Phase 2 Version Final 1.0 + Amendment 1.0 (September 24, 2012) + Amendment 2.0 (October 17, 2012) + Amendment 3.0 (December 18, 2012) + Amendment 4.0 (May 02, 2013) Date of Protocol July 05, 2012 Amendment 4.0 (May 02, 2013) This document is strictly confidential. Disclosure of contents or any trial-related information to third parties other than applicable IEC(s)/IRB(s) and regulatory authorities is not permitted except by written consent of AiCuris GmbH & Co. KG. CONFIDENTIAL page 1 of 125 Downloaded From: https://jamanetwork.com/ on 09/25/2021 Downloaded From: https://jamanetwork.com/ on 09/25/2021 Downloaded From: https://jamanetwork.com/ on 09/25/2021 Downloaded From: https://jamanetwork.com/ on 09/25/2021 Version 1.0 + Amnd 1.0 Clinical Trial Protocol + Amnd 2.0, 3.0 + 4.0 AIC316-01-II-02 May 02, 2013 1.2 Declaration by the Principal Investigator I have read this protocol and agree that it contains all the necessary details for carrying out this trial. I agree to personally conduct or supervise the trial-related activities at my investigative site as described in this protocol and will complete the trial-related activities for all enrolled subjects within the time designated for the trial. I verify that I am suitably qualified by my education, scientific medical training and experience to conduct the trial. Documentation of my qualifications and professional affiliations are contained in my signed and dated current curriculum vitae. I will provide the supplied copies of the protocol and all information relating to non-clinical and prior clinical experience (e.g., Investigator’s Brochure [IB]) to all staff in my unit who participates in this trial. I will discuss this material with them to ensure that they are fully conversant with the medical treatment in, and the conduct of, the trial, and that they will handle the data and information generated in the trial confidentially. I agree not to start enrolling subjects until a duly appointed Ethics Committee (EC)/Institutional Review Board (IRB) has issued a favorable opinion and the Competent Authorities (CA) have approved the trial. I will conduct the trial in accordance with Good Clinical Practice (GCP), the Declaration of Helsinki, and the moral, ethical and scientific principles that justify medical research. The trial will be conducted in accordance with the relevant laws and regulations relating to clinical trials and the protection of subjects in the country in which I will perform the trial. All subjects will be comprehensively informed about the nature of the trial, of its investigational nature and that they may withdraw from the trial at any time. They will give their written consent to participate before entry into the trial. I will only use the subject information sheet and informed consent form approved by AiCuris GmbH & Co. KG and the EC/IRB which has reviewed this trial. I will supply AiCuris GmbH & Co. KG any material written by myself (e.g., summary of trial, correspondence, etc.) which has been given to the EC/IRB in support of the application. I have read the current version of the IB, including the potential risks (especially the results of the pharmacological and toxicological examination) and adverse drug effects of the investigational medicinal product obtained in previous clinical trials and I agree to report all adverse events (AEs) that occur during the trial. Where applicable, the information contained in the electronic case report forms (eCRFs) will be transcribed from my records, reports and manuscripts. The eCRF may be the original source for certain items. Either I, or an appointed person, will attest to the authenticity of the data and accuracy and completeness of the transcriptions by providing an electronic signature in the eCRF. I agree to the audit and monitoring procedures described in the protocol which involve verification of trial records against the original records. I will make available additional background data from my records at the request of government regulatory agencies, if allowed by the hospital or institution where the trial is being conducted. I am aware of the requirements for the correct reporting of serious AEs, and I undertake to document and to report such events as requested. I understand that I am obliged to provide the complete results and all data generated during the trial to AiCuris GmbH & Co. KG for their unrestricted use. I understand and agree that such trial results, data, CONFIDENTIAL page 3 of 125 Downloaded From: https://jamanetwork.com/ on 09/25/2021 Version 1.0 + Amnd 1.0 Clinical Trial Protocol + Amnd 2.0, 3.0 + 4.0 AIC316-01-II-02 May 02, 2013 and all information concerning the investigational medicinal product(s) and AiCuris GmbH & Co. KG’s activities, such as patents, formulae, manufacturing procedures and basic, unpublished scientific data and information supplied by AiCuris GmbH & Co. KG or generated during the trial are confidential, and are the exclusive property of AiCuris GmbH & Co. KG. I undertake only to use this information plus the investigational medicinal product to conduct the trial and not to use it for any other purpose without the written agreement of AiCuris GmbH & Co. KG. I will supply AiCuris GmbH & Co. KG with the trial data in such a way that the subjects cannot be personally identified. As the Principal Investigator I will also adhere to the given detailed investigator responsibilities as specified in Appendix 20.1 of this protocol. Investigator Signature date Name and Address* Telephone number* * If the address or phone number of the Investigator changes during the course of the trial, written notification will be provided by the Investigator to the AiCuris GmbH & Co. KG and Inc. This will not require protocol amendment(s). CONFIDENTIAL page 4 of 125 Downloaded From: https://jamanetwork.com/ on 09/25/2021 Version 1.0 + Amnd 1.0 Clinical Trial Protocol + Amnd 2.0, 3.0 + 4.0 AIC316-01-II-02 May 02, 2013 1.3 Involved Parties 1. Sponsor’s Medical Burkhard Timmler, MD Director AiCuris GmbH & Co. KG Friedrich-Ebert-Straße 475 / Building 302 42117 Wuppertal, Germany Office phone: +49 (0) 202 31763 Office fax: +49 (0) 202 31763 Email: 2. Coordinating Investigator Anna Wald, MD, MPH University of Washington Virology Research Clinic 908 Jefferson St, Suite 11NJ-1166, Seattle, WA 98104, USA Office phone: Office fax: 3. Sponsor’s Clinical Trial Christiane Vank, PhD Manager AiCuris GmbH & Co. KG Friedrich-Ebert-Straße 475 42117 Wuppertal, Germany Office phone: 49 202 31763 Office fax: 49 202 31763 Email: 4. CRO’s Clinical Trial Manager : 5. Statistical analysis CONFIDENTIAL page 5 of 125 Downloaded From: https://jamanetwork.com/ on 09/25/2021 Version 1.0 + Amnd 1.0 Clinical Trial Protocol + Amnd 2.0, 3.0 + 4.0 AIC316-01-II-02 May 02, 2013 6. Sponsor’s Dirk Kropeit, MD Pharmacokineticist AiCuris GmbH & Co. KG Friedrich-Ebert-Straße 475 42117 Wuppertal, Germany Office phone: 49 202 31763 Office fax: 49 202 31763 Email: 7. Bioanalysis of pharmacokinetic samples and samples for evaluation of potential drug metabolites 8. Analysis of routine blood and urine samples 9. Pharmacovigilance (SAE reporting) 10. HSV Western Blot, Anne Cent University of Washington, Virology Laboratory Children’s Hospital & Medical Center Room W8814 4800 Sand Point Way N. E. Seattle, WA 98105, USA Office phone: Email: CONFIDENTIAL page 6 of 125 Downloaded From: https://jamanetwork.com/ on 09/25/2021 Version 1.0 + Amnd 1.0 Clinical Trial Protocol + Amnd 2.0, 3.0 + 4.0 AIC316-01-II-02 May 02, 2013 11. HSV DNA PCR, Meei-Li Huang Sequencing University of Washington Molecular Diagnostic Laboratory 1616 Eastlake Ave E, Suite 320 Seattle, WA 98102, USA Office Phone: E-Mail: 12. Preparation and supply of Trial medication kits 13. Pharmacogenetic analysis CONFIDENTIAL page 7 of 125 Downloaded From: https://jamanetwork.com/ on 09/25/2021 Version 1.0 + Amnd 1.0 Clinical Trial Protocol + Amnd 2.0, 3.0 + 4.0 AIC316-01-II-02 May 02, 2013 2 PROTOCOL SYNOPSIS Trial No. AIC-316-01-II-02 Title A double-blind, double dummy, randomized cross-over trial to compare the effect of AIC316 100 mg once daily versus valacyclovir 500 mg once daily on genital HSV shedding in HSV-2 seropositive adults. Trial Identification AIC-316-01-II-02 Code Clinical Phase 2 Trial design Approximately ninety subjects with proven recurrent episodes of genital herpes will be randomized to receive an oral daily dose of either AIC316 100 mg or valacyclovir 500 mg for 28 days, then to undergo a 4 week washout period, followed by a second 28 day period receiving the corresponding other treatment (cross over design), and ending with a 28 day follow up period. Appropriate matching placebo will be administered in parallel to the verum. During both, the first and second treatment period, subjects will obtain swabs of the genital secretions 4 times a day and maintain a diary of genital signs and symptoms.
Load more

Recommended publications
  • Aicuris Granted Fast Track Designation by U.S. FDA for Oral Pritelivir for Treatment of HSV Infections in Immunocompromised Adults
    AiCuris Granted Fast Track Designation by U.S. FDA for Oral Pritelivir for Treatment of HSV Infections in Immunocompromised Adults Wuppertal, August 01, 2017 - AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, today announced that the Company has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for oral pritelivir, AiCuris’ lead candidate for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised adults. Fast track is a process designed to facilitate the development, expedite the review and accelerate the approval process of drugs to treat serious conditions and fill an unmet medical need, with the purpose of getting important new drugs to patients sooner. Oral pritelivir, a small molecule helicase-primase inhibitor with a novel mode of action, is currently in a clinical phase 2 study, called PRIOH-1, in the U.S. to evaluate the product candidate’s efficacy and safety compared to i.v. foscarnet, a virostatic agent which is used mainly for the treatment of herpes viruses resistant to other antiviral drugs. In a prior phase 2 study, oral pritelivir showed to significantly improve the suppression of viral shedding compared to the current standard of care for genital HSV-2 infections, the nucleoside analog valacyclovir. The results of this study were published in the Journal of the American Medical Association (JAMA) earlier this year. “The decision by the FDA to grant fast track designation to oral pritelivir underscores that our product might fill the major need for innovative, more efficacious therapies for immunocompromised patients with HSV infections that have become resistant to standard treatments,” said Dr.
    [Show full text]
  • Herpes Simplex Virus
    HSV Herpes simplex virus HSV (Herpes simplex virus) can be spread when an infected person is producing and shedding the virus. Herpes simplex can be spread through contact with saliva, such as sharing drinks. Symptoms of herpes simplex virus infection include watery blisters in the skin or mucous membranes of the mouth, lips or genitals. Lesions heal with ascab characteristic of herpetic disease. As neurotropic and neuroinvasive viruses, HSV-1 and -2 persist in the body by becoming latent and hiding from the immune system in the cell bodies of neurons. After the initial or primary infection, some infected people experience sporadic episodes of viral reactivation or outbreaks. www.MedChemExpress.com 1 HSV Inhibitors (Z)-Capsaicin 1-Docosanol (Zucapsaicin; Civamide; cis-Capsaicin) Cat. No.: HY-B1583 (Behenyl alcohol) Cat. No.: HY-B0222 (Z)-Capsaicin is the cis isomer of capsaicin, acts 1-Docosanol is a saturated fatty alcohol used as an orally active TRPV1 agonist, and is used in traditionally as an emollient, emulsifier, and the research of neuropathic pain. thickener in cosmetics, and nutritional supplement; inhibitor of lipid-enveloped viruses including herpes simplex. Purity: 99.96% Purity: ≥98.0% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 50 mg Size: 500 mg 2-Deoxy-D-glucose 20(R)-Ginsenoside Rh2 (2-DG; 2-Deoxy-D-arabino-hexose; D-Arabino-2-deoxyhexose) Cat. No.: HY-13966 Cat. No.: HY-N1401 2-Deoxy-D-glucose is a glucose analog that acts as 20(R)-Ginsenoside Rh2, a matrix a competitive inhibitor of glucose metabolism, metalloproteinase (MMP) inhibitor, acts as a inhibiting glycolysis via its actions on hexokinase.
    [Show full text]
  • Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2
    viruses Review Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2 Lauren A. Sadowski 1,†, Rista Upadhyay 1,2,†, Zachary W. Greeley 1,‡ and Barry J. Margulies 1,3,* 1 Towson University Herpes Virus Lab, Department of Biological Sciences, Towson University, Towson, MD 21252, USA; [email protected] (L.A.S.); [email protected] (R.U.); [email protected] (Z.W.G.) 2 Towson University Department of Chemistry, Towson, MD 21252, USA 3 Molecular Biology, Biochemistry, and Bioinformatics Program, Towson University, Towson, MD 21252, USA * Correspondence: [email protected] † Authors contributed equally to this manuscript. ‡ Current address: Becton-Dickinson, Sparks, MD 21152, USA. Abstract: Herpes simplex viruses-1 and -2 (HSV-1 and -2) are two of the three human alphaher- pesviruses that cause infections worldwide. Since both viruses can be acquired in the absence of visible signs and symptoms, yet still result in lifelong infection, it is imperative that we provide interventions to keep them at bay, especially in immunocompromised patients. While numerous experimental vaccines are under consideration, current intervention consists solely of antiviral chemotherapeutic agents. This review explores all of the clinically approved drugs used to prevent the worst sequelae of recurrent outbreaks by these viruses. Keywords: acyclovir; ganciclovir; cidofovir; vidarabine; foscarnet; amenamevir; docosanol; nelfi- navir; HSV-1; HSV-2 Citation: Sadowski, L.A.; Upadhyay, R.; Greeley, Z.W.; Margulies, B.J. Current Drugs to Treat Infections 1. Introduction with Herpes Simplex Viruses-1 and -2. The world of anti-herpes simplex (anti-HSV) agents took flight in 1962 with the FDA Viruses 2021, 13, 1228.
    [Show full text]
  • Influenza Sampler
    Influenza Sampler Presenting sample chapters on influenza from the Manual of Clinical Microbiology, 12th Edition, Chapter 86 “Influenza Viruses” by Robert L. Atmar This chapter discusses seasonal influenza strains as well as novel swine and avian influenza strains that can infect people and have pandemic potential. Chapter 83 “Algorithms for Detection and Identification of Viruses” by Marie Louise Landry, Angela M. Caliendo, Christine C. Ginocchio, Randall Hayden, and Yi-Wei Tang This chapter outlines technological advances for the diagnosis of viral infections. Chapter 113 “Antiviral Agents” by Carlos A.Q. Santos and Nell S. Lurian This chapter reviews antiviral agents approved by FDA and their mechanism(s) of action. Photo Credit: CDC/ Douglas Jordan, Dan Higgins Influenza Viruses* ROBERT L. ATMAR Send proofs to: Robert L. Atmar Email: [email protected] and to editors: [email protected] [email protected] [email protected] 86 TAXONOMY The segmented genome of influenza viruses allows the The influenza viruses are members of the family Orthomyxo- exchange of one or more gene segments between two viruses viridae. Antigenic differences in two major structural pro- when both infect a single cell. This exchange is called teins, the matrix protein (M) and the nucleoprotein (NP), genetic reassortment and results in the generation of new and phylogenetic analyses of the virus genome are used to strains containing a mix of genes from both parental viruses. separate the influenza viruses into four genera within the Genetic reassortment between human and avian influenza family: Influenzavirus A, Influenzavirus B, Influenzavirus C, virus strains led to the generation of the 1957 H2N2 and and Influenzavirus D.
    [Show full text]
  • Treatment of Herpes Simplex Virus Infection Using Antiviral Sirna Swarms with 2′-Fluoro-Modifications
    Treatment of herpes simplex virus infection using antiviral siRNA swarms with 2′-fluoro-modifications Master’s Thesis University of Turku MSc Degree Programme in Biomedical Sciences Drug Discovery and Development 4/2020 Kiira Kalke Supervised by Veijo Hukkanen & Henrik Paavilainen* Institute of Biomedicine *current address: Orion Pharma The originality of this thesis has been verified in accordance with the University of Turku quality assurance system using the Turnitin Originality Check service UNIVERSITY OF TURKU Institute of Biomedicine, Faculty of Medicine KALKE, KIIRA: Treatment of herpes simplex virus infection using antiviral siRNA swarms with 2’-fluoro-modifications Master’s Thesis, 94 p MSc Degree Programme in Biomedical Sciences, Drug Discovery and Development April 2020 Herpes simplex virus 1 (HSV-1) is a very common pathogen. Besides mostly harmless oral lesions, HSV-1 causes severe diseases such as neonatal herpes, herpes encephalitis and herpes keratitis, the primary cause of infectious blindness worldwide. The available anti-herpes chemotherapy is efficient but depends on a functional viral thymidine kinase. Long-term treatment, required especially in severe diseases, promotes emergence of thymidine kinase mutant strains. These strains are multi-drug resistant, and may lead to dangerous untreatable exacerbations, demonstrating an evident unmet medical need. Small interfering RNA (siRNA) swarms are a novel antiviral approach with extensive tolerance for pathogen mutations. In contrast to regular siRNAs targeting around twenty nucleotides, swarms can target thousands, and thus overcome major challenges of regular antiviral-siRNAs, such as emergence of resistant mutant strains. The most extensively studied siRNA swarm target is the essential UL29 gene of HSV-1. The UL29 targeting siRNA swarm has proven antiviral efficacy against multiple patient-derived strains in vitro and significant inhibition of virus replication in vivo.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Current Antivirals and Novel Botanical Molecules Interfering with Herpes Simplex Virus Infection
    fmicb-11-00139 February 7, 2020 Time: 15:12 # 1 REVIEW published: 11 February 2020 doi: 10.3389/fmicb.2020.00139 Current Antivirals and Novel Botanical Molecules Interfering With Herpes Simplex Virus Infection Diana M. Álvarez1, Estefanía Castillo1, Luisa F. Duarte1, José Arriagada1, Nicolás Corrales1, Mónica A. Farías1, Adolfo Henríquez2, Cristian Agurto-Muñoz2,3 and Pablo A. González1* 1 Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile, 2 Centro de Biotecnología, Universidad de Concepción, Concepción, Chile, 3 Departamento de Ciencia y Tecnología de Alimentos, Facultad de Farmacia, Universidad de Concepción, Concepción, Chile Herpes simplex viruses type 1 (HSV-1) and type 2 (HSV-2) are highly prevalent within the human population and are characterized by lifelong infections and sporadic recurrences due to latent neuron infection. Upon reactivations, HSVs may manifest either, symptomatically or asymptomatically and be shed onto others through mucosae body fluids. Although, HSVs can produce severe disease in humans, such as life- Edited by: threatening encephalitis and blindness, the most common symptoms are skin and Michael Nevels, mucosal lesions in the oro-facial and the genital areas. Nucleoside analogs with antiviral University of St Andrews, activity can prevent severe HSV infection, yet they are not very effective for treating skin United Kingdom manifestations produced by these viruses, as they only reduce in a few days at most Reviewed by: David Leib, the duration of lesions. Additionally, HSV variants that are resistant to these antivirals Dartmouth College, United States may arise, especially in immunosuppressed individuals.
    [Show full text]
  • Two Recent Publications on Pritelivir Confirm the Potency of the Novel Aicuris Anti-Herpes Simplex Virus Drug
    Two Recent Publications on Pritelivir Confirm the Potency of the Novel AiCuris Anti-Herpes Simplex Virus Drug • Clinical data published in the peer-reviewed “Journal of Infectious Diseases” showed no evidence of resistance in HSV-2 sequences obtained from genital swabs collected during a phase II trial • Pritelivir clinical phase II data were used for the development of a mathematical model to optimize dose selection for clinical trials published in the renowned journal “Science Translational Medicine” Wuppertal, Germany, June 23, 2016 - AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, announced today the publication of results assessing molecular signals of drug resistance over 28 days of therapy; this was a secondary objective from a recent phase II dose finding study with pritelivir. The peer-reviewed article titled: “No evidence of resistance of HSV-2 to pritelivir following four weeks of daily therapy” was prepared in collaboration with Dr. Paul Edlefsen and colleagues at the Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington, USA, and will be published in the July issue of “The Journal of Infectious Diseases”. Pritelivir belongs to a new class of antiviral compounds, the helicase-primase inhibitors, being developed to treat herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections. Oral pritelivir has successfully completed a phase II clinical trial in 156 participants with genital HSV-2 infections showing reduced viral shedding and genital lesions. The mentioned peer-reviewed article reports the results of a secondary objective of this clinical study.
    [Show full text]
  • Supplementary Information Table S1. Approved, Investigational
    Supplementary information Table S1. Approved, investigational and experimental antiviral agents and their side effects (if known). Agent Status Virus Potential target Reference* Side effects, if known Abacavir Approved HIV-1 HIV-1 RT DB01048 Allergic reactions, lactic acidosis, liver toxicity, risk of heart attack, nausea, vomiting, lethargy, fever, headache, HIV-2 HIV-2 RT diarrhea. Aciclovir Approved HSV-1 HSV-1 DNA pol DB00787 HSV-2 HSV-2 DNA pol Nausea, diarrhea, headache, vomiting, VZV VZV DNA pol kidney toxicity, low platelets. Weakness, headache, fever, increased cough, nausea, vomiting, diarrhea, skin Adefovir Approved HBV HBV RT DB13868 rash. Skin reactions, photosensitivity, Alitretinoin Approved HHV-8 Human RARA DB00523 numbness, muscle aches. Nausea, diarrhea, constipation, headache, insomnia, blurred vision, loss of Amantadine Approved FLUAV FLUAV M2 DB00915 coordination, rash, confusion. Gastrointestinal symptoms (nausea, abdominal pain, diarrhea), paresthesia, Amprenavir Approved HIV-1 HIV-1 RT DB00701 depression, rash. Flu-like symptoms, hair loss, nausea, rash, Asunaprevir Approved HCV HCV protease DB11586 anemia, clotting problems, liver toxicity. Atazanavir Approved HIV-1 HIV-1 RT DB01072 Arrhythmia, rash, liver toxicity, flu-like HIV-2 HIV-2 RT symptoms. BCX4430 Approved HCV HCV RNA pol DB11676 N. a. Brivudine Approved HSV-1 HSV-1 DNA pol DB03312 Nausea, headache, lowered blood cell VZV VZV DNA pol counts, liver toxicity, allergic reactions. Headache, nausea, vomiting, abdominal Cidofovir Approved CMV CMV DNA pol DB00369 pain, rash, liver toxicity. Cobicistat Approved HIV-1 HIV-1 integrase DB09065 Nausea, dizziness, liver and kidney HIV-2 HIV-2 integrase toxicity, Headache, nausea, diarrhea, insomnia, Daclatasvir Approved HCV HCV NS5A DB09102 rash, anemia.
    [Show full text]
  • Repurposing of FDA Approved Drugs
    Antiviral Drugs (In Phase IV) ABACAVIR GEMCITABINE ABACAVIR SULFATE GEMCITABINE HYDROCHLORIDE ACYCLOVIR GLECAPREVIR ACYCLOVIR SODIUM GRAZOPREVIR ADEFOVIR DIPIVOXIL IDOXURIDINE AMANTADINE IMIQUIMOD AMANTADINE HYDROCHLORIDE INDINAVIR AMPRENAVIR INDINAVIR SULFATE ATAZANAVIR LAMIVUDINE ATAZANAVIR SULFATE LEDIPASVIR BALOXAVIR MARBOXIL LETERMOVIR BICTEGRAVIR LOPINAVIR BICTEGRAVIR SODIUM MARAVIROC BOCEPREVIR MEMANTINE CAPECITABINE MEMANTINE HYDROCHLORIDE CARBARIL NELFINAVIR CIDOFOVIR NELFINAVIR MESYLATE CYTARABINE NEVIRAPINE DACLATASVIR OMBITASVIR DACLATASVIR DIHYDROCHLORIDE OSELTAMIVIR DARUNAVIR OSELTAMIVIR PHOSPHATE DARUNAVIR ETHANOLATE PARITAPREVIR DASABUVIR PENCICLOVIR DASABUVIR SODIUM PERAMIVIR DECITABINE PERAMIVIR DELAVIRDINE PIBRENTASVIR DELAVIRDINE MESYLATE PODOFILOX DIDANOSINE RALTEGRAVIR DOCOSANOL RALTEGRAVIR POTASSIUM DOLUTEGRAVIR RIBAVIRIN DOLUTEGRAVIR SODIUM RILPIVIRINE DORAVIRINE RILPIVIRINE HYDROCHLORIDE EFAVIRENZ RIMANTADINE ELBASVIR RIMANTADINE HYDROCHLORIDE ELVITEGRAVIR RITONAVIR EMTRICITABINE SAQUINAVIR ENTECAVIR SAQUINAVIR MESYLATE ETRAVIRINE SIMEPREVIR FAMCICLOVIR SIMEPREVIR SODIUM FLOXURIDINE SOFOSBUVIR FOSAMPRENAVIR SORIVUDINE FOSAMPRENAVIR CALCIUM STAVUDINE FOSCARNET TECOVIRIMAT FOSCARNET SODIUM TELBIVUDINE GANCICLOVIR TENOFOVIR ALAFENAMIDE GANCICLOVIR SODIUM TENOFOVIR ALAFENAMIDE FUMARATE TIPRANAVIR VELPATASVIR TRIFLURIDINE VIDARABINE VALACYCLOVIR VOXILAPREVIR VALACYCLOVIR HYDROCHLORIDE ZALCITABINE VALGANCICLOVIR ZANAMIVIR VALGANCICLOVIR HYDROCHLORIDE ZIDOVUDINE Antiviral Drugs (In Phase III) ADEFOVIR LANINAMIVIR OCTANOATE
    [Show full text]
  • HIV/AIDS Guidelines
    Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America How to Cite the Adult and Adolescent Opportunistic Infection Guidelines: Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed (insert date) [include page numbers, table number, etc. if applicable] It is emphasized that concepts relevant to HIV management evolve rapidly. The Panel has a mechanism to update recommendations on a regular basis, and the most recent information is Access AIDSinfo available on the AIDSinfo website (http://aidsinfo.nih.gov). mobile site What’s New in the Guidelines Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV document is published in an electronic format that can be easily updated as relevant changes in prevention and treatment recommendations occur. The editors and subject matter experts are committed to timely changes in this document because so many health care providers, patients, and policy experts rely on this source for vital clinical information. All changes are developed by the subject matter groups listed in the document (changes in group composition are also promptly posted).
    [Show full text]